SLR OF ECONOMIC EVALUATION FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN UK

被引：0
|
作者：
Mehta, J. [1 ]
Harrison, O. [2 ]
Barwood, C. [3 ]
Ubi, S. [3 ]
Bertranou, E. [2 ]
Bouhlabel, F. [4 ]
Low, E. [5 ]
Shah, A. [6 ]
Korde, R. [4 ]
Shah, J. [4 ]
Gaugris, S. [3 ]
机构：
[1] Karyopharm Therapeut, Lexington, MA USA
[2] FIECON, London, Lon, England
[3] FIECON Ltd, St Albans, Hrt, England
[4] Karyopharm Therapeut, Newton, MA USA
[5] Eric Low Consulting, East Lothian, Scotland
[6] Karyopharm Therapeut, Boston, MA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN165
引用
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [31] Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis
    Banerjee, Rahul
    Hasegawa, Ken
    Itani, Taha
    Giordana, Monique
    Granados, Enrique
    Rosado, Margrit B.
    Chan, Rebecca J.
    Kostic, Ana
    Kanters, Steve
    Zoratti, Michael J.
    Leleu, Xavier
    BLOOD, 2024, 144 : 4721 - 4722
  • [32] Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Abadier, Michael
    Estevam, Jose
    Berg, Deborah
    Fedyk, Eric Robert
    BLOOD, 2020, 136
  • [33] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [34] Patient preferences for treatment decisions in relapsed/refractory multiple myeloma (RRMM) treatment: results of the PARTNER-project
    Sillis, Laure
    Panis, Laura Int
    Van Hecke, Ann
    Foulon, Veerle
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (03) : 775 - 776
  • [35] Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Ibrahim, Emad
    Vallurupalli, Anusha
    Cull, Elizabeth H.
    Green, Damian J.
    Oliver, Kate
    Longcor, Jarrod
    BLOOD, 2019, 134
  • [36] Patient Characteristics, Treatment Patterns and Outcomes Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients in Japan
    Jun, Gyungjin
    Luptakova, Katarina
    Koizumi, Hiroo
    Iwasaki, Kosuke
    Hiroi, Shinzo
    Soeda, Junpei
    BLOOD, 2016, 128 (22)
  • [37] Total costs of therapy with lenalidomide or bortezomib in relapsed/refractory multiple myeloma (rrMM).
    Borrello, Ivan
    Binder, Gary
    Khan, Zeba M.
    Pashos, Chris L.
    Durie, Brian G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM)
    Pennipede, Dante
    Mohyuddin, Ghulam Rehman
    Hawkins, Ryan
    Ganguly, Siddhartha
    Shune, Leyla
    Ahmed, Nausheen
    Mohan, Meera
    Cui, Wei
    Mahmoudjafari, Zahra
    McGuirk, Joseph
    Atrash, Shebli
    Abdallah, Al-Ola
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (06) : 602 - 608
  • [39] Treatment Patterns in Patients (pts) with Refractory/Relapsed Multiple Myeloma (RRMM) in Germany between 2016 and 2018
    Merz, Maximilian
    Patel, Vishal
    Kutikova, Lucie
    Lebioda, Andrea
    Schoehl, Martina
    Kellermann, Lenka
    Goldschmidt, Hartmut
    BLOOD, 2019, 134
  • [40] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
12345